Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity

Article Oncology

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui et al.

Summary: The study found a high risk of mortality among MPN patients during COVID-19 infection, especially in MF patients and those discontinuing Ruxo treatment. Further investigation is needed on the role of Ruxo treatment and its interruption in affecting mortality in MPN patients with COVID-19.

LEUKEMIA (2021)

Add to Collection

Article Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Fulvia Pimpinelli et al.

Summary: The study assessed the safety and immunogenicity of the BNT162b2 mRNA vaccine in hematological patients, finding lower response rates in multiple myeloma patients. It suggests that these patients should continue to maintain protective measures and monitor vaccine effectiveness post-vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose

Fabio Fiorino et al.

Summary: Immunization with mRNA SARS-CoV-2 vaccines in patients with myelofibrosis (MF) leads to slower kinetics of antibody responses, especially in those treated with ruxolitinib. The study suggests the potential need for a third vaccine dose in these patients.

BIOMEDICINES (2021)

Add to Collection

Article Hematology

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Katrin Herzog Tzarfati et al.

Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Letter Hematology

Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib

Paola Guglielmelli et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Francesco Passamonti et al.

Summary: The study found a low rate of seroconversion in patients with hematological malignancies, possibly due to treatment-mediated immune dysfunction.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Letter Hematology

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms

Onima Chowdhury et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Letter Oncology

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Fulvia Pimpinelli et al.

Summary: Among 42 Philadelphia negative myeloproliferative neoplasm patients receiving systemic active treatment, those with myelofibrosis showed significantly lower response to the anti-SARS-CoV-2 BNT162b2 vaccine compared to patients with essential thrombocythemia and polycythemia vera in terms of IgG titers and seroprotection rates. The ongoing treatment with Ruxolitinib in some patients may be associated with reduced vaccine immunogenicity, but further large prospective studies are needed to confirm this finding.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Letter Oncology

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

Patrick Harrington et al.

LEUKEMIA (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Sokratis A. Apostolidis et al.

Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.

NATURE MEDICINE (2021)

Add to Collection

Review Oncology

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios

Francesca Palandri et al.

Summary: MPN patients, especially those with essential thrombocythemia, seem to have a high risk of severe COVID-19, while the risk is not negligible in myelofibrosis patients. These patients are at high risk for both thrombotic and hemorrhagic complications, which should be taken into account on a case-by-case basis when determining the likelihood of COVID-19 infection. There is currently no evidence to suggest that hydroxyurea or interferon affects COVID-19 risk or severity. On the other hand, while ruxolitinib's immunosuppressive activity may increase the risk of infection, abruptly stopping its use during COVID-19 is associated with worse outcomes. Vaccination against COVID-19 is recommended for all MPN patients, with reassuring data available on the efficacy of mRNA vaccines.

CANCERS (2021)

Add to Collection

Article Hematology